MIDATECH PHARMA
R&D | Autoimmune Diseases

GNP Drug Conjugates: Immunotherapy

Based on prior research which evaluated the effect of Midatech GNPs on the immune system in both autoimmune disease and cancer settings, several research programs are underway in immunotherapeutic applications.  
 
In autoimmune disease, where the host’s immune system attacks the host’s own healthy cells, GNP bound peptides have been shown to preferentially influence and target specific immune  components such as dendritic cells and T-cells and distribute rapidly to lymphoid tissues around the body resulting in a tolerogenic response that moderates the unwanted immune response to normal healthy cells. Midatech GNPs can be chemically linked to molecules of self-peptide or small antigens that are important in autoimmune diseases such as type 1 diabetes – so called antigen specific immunotherapy (ASI). ASI has the advantage over biologics and other immunotherapies in that it focuses on disease causing antigens only and does not compromise the rest of the immune system, and therefore is likely to have a much improved safety profile and be suitable for use not only at disease onset but also in disease prevention and in children. Midatech’s GNP technology as an enabling platform is being developed to boost the potential of ASI administered antigen to generate a tolerogenic rather than immunogenic response.  
 
In cancer, GNP bound epitopes (the binding site of a tumour antigen) have previously demonstrated increased anti-tumour T-cell responses that attack tumour cells. Midatech’s GNP particles can thus be designed and configured to be either selectively immunosuppressant as potential treatment for autoimmune disease, or immunostimulatory to treat cancers, depending on what agents are attached to the GNPs.

 

R&D
R&D
Autoimmune Diseases

GNP Drug Conjugates: Immunotherapy

Based on prior research which evaluated the effect of Midatech GNPs on the immune system in both autoimmune disease and cancer settings, several research programs are underway in immunotherapeutic applications.  
 
In autoimmune disease, where the host’s immune system attacks the host’s own healthy cells, GNP bound peptides have been shown to preferentially influence and target specific immune  components such as dendritic cells and T-cells and distribute rapidly to lymphoid tissues around the body resulting in a tolerogenic response that moderates the unwanted immune response to normal healthy cells. Midatech GNPs can be chemically linked to molecules of self-peptide or small antigens that are important in autoimmune diseases such as type 1 diabetes – so called antigen specific immunotherapy (ASI). ASI has the advantage over biologics and other immunotherapies in that it focuses on disease causing antigens only and does not compromise the rest of the immune system, and therefore is likely to have a much improved safety profile and be suitable for use not only at disease onset but also in disease prevention and in children. Midatech’s GNP technology as an enabling platform is being developed to boost the potential of ASI administered antigen to generate a tolerogenic rather than immunogenic response.  
 
In cancer, GNP bound epitopes (the binding site of a tumour antigen) have previously demonstrated increased anti-tumour T-cell responses that attack tumour cells. Midatech’s GNP particles can thus be designed and configured to be either selectively immunosuppressant as potential treatment for autoimmune disease, or immunostimulatory to treat cancers, depending on what agents are attached to the GNPs.

 

© Copyright 2017 Midatech Pharma PLC